Dr. Chesselet is the Charles H. Markham Professor of Neurology and distinguished professor in the Departments of Neurology and Neurobiology at UCLA. She was the Chair of the Neurobiology Department from 2002 to 2013 and is currently the Director of the Integrative Center for Neural Repair which includes the Center for the Study of Parkinson’s Disease at UCLA that she created in 1998. Read her full bio here.
Philippe Walker, Ph.D., Chief Scientific Officer of NEOMED will speak at our symposium. Dr. Walker leads a team of project directors who jointly support the advancement of the NEOMED portfolio. He ensures that efficient project strategies are established and implemented to deliver high quality drug candidates that meet multinational Pharma standards. Full bio here.
Tom Blackburn, Ph.D., DSc. if Founder and CEO of Translational Pharmacology Bioventures LLC. (TPBioventures) Dr. Blackburn has over 25 years of experience in drug discovery research in the Pharmaceutical/Biotechnology sectors and in the discovery of innovative therapeutics for the treatment of CNS disorders. He has published over 200 papers, abstracts, chapters and presentations in the field of neuroscience and is an inventor on over 21 patents. He has been President of the British Pharmacological Society. Read more here.
Dale Corbett, Ph.D. is confirmed to speak at Biotechnology & Human Health 2014. Dr. Dale Corbett is currently a Professor of Neurosciences in the Department of Cellular and Molecular Medicine at the University of Ottawa and Scientific Director and CEO of the Heart and Stroke Foundation Canadian Partnership for Stroke Recovery. Prior to his relocation to the University of Ottawa in September 2010, Dr. Corbett held a Tier I Canada Research Chair in Stroke and Neuroplasticity at Memorial University. Dr. Corbett obtained his PhD from Concordia University followed by post-doctoral studies at McGill University. He was the first recipient of the Paul Morley Mentorship Award from Canadian Stroke Network in recognition of his outstanding contributions to training new investigators in the stroke research field. Full bio here.
Dr. Christian H. Fibiger is a professor emeritus University of British Columbia, Psychiatry and renowned scientist and consultant in the field of neuroscience. He has authored more than 400 scientific papers focused primarily on Alzheimer’s disease, schizophrenia, depression and drug abuse. He currents works as Chief Scientific Officer with MedGenesis Therapeutix, a “privately-held biopharmaceutical company committed to developing and commercializing innovative therapeutics to provide life-enhancing treatments to patients with serious neurologic diseases. MedGenesis is a worldwide leader in Convection Enhanced Delivery (CED), a minimally invasive technique that provides for targeted, local treatment of CNS conditions such as Parkinson’s disease, Epilepsy, Brain Cancer and other severely debilitating diseases of the CNS.” (www.medgenesis.com) Full bio here.
Charles K. Meschul, Ph.D. is a professor in the Department of Behaviorial Neuroscience and Pathology (OHSU) along with Research Biologist and Director, Electron Microscopy Facility (VA). Dr. Meshul’s research involves investigating electron microscopic/immuno-cytochemical changes in synapses within the brain following various drug treatment procedures or lesions of the nigrostriatal pathway, as a model for Parkinson’s disease. Read full bio here.